Citius Oncology (CTOR) Stock Price, News & Analysis

Company Overview

Citius Oncology, Inc. (NASDAQ: CTOR) is an oncology-focused biopharmaceutical company dedicated to developing and commercializing therapies for patients with cancer. The company operates as a subsidiary of Citius Pharmaceuticals, Inc. and is focused primarily on treatments for hematologic malignancies.

Citius Oncology’s lead product is LYMPHIR (denileukin diftitox-cxdl), an immunotherapy designed to target and eliminate cancer cells that express the interleukin-2 receptor. In August 2024, the U.S. Food and Drug Administration approved LYMPHIR for the treatment of relapsed or refractory cutaneous T-cell lymphoma in adults after at least one prior systemic therapy. The product was formerly known as E7777 and is intended for use in the United States oncology market.

The company’s activities center on supporting the commercialization of LYMPHIR and advancing its oncology-focused development and business strategy. Citius Oncology is led by executives associated with its parent company, Citius Pharmaceuticals, including Chairman and Chief Executive Officer Myron Holubiak. Its current commercial focus is the U.S. market, with potential expansion depending on regulatory approvals and future corporate partnerships.

Key Stats

• Today's Range: $0.57 to $0.65
• 50-Day Range: $0.58 to $1.14
• 52-Week Range: $0.49 to $1.93
• Volume: 134,831 shs
• Average Volume: N/A
• Market Capitalization: $56.81 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Citius Oncology Stock Analysis - MarketRank™

Citius Oncology scored higher than 25% of companies evaluated by MarketBeat, and ranked 797th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Citius Oncology has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Citius Oncology has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Citius Oncology is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Citius Oncology is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.27% of the float of Citius Oncology has been sold short.

Short Interest Ratio / Days to Cover

Citius Oncology has a short interest ratio ("days to cover") of 2.68, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Citius Oncology has recently decreased by 21.49%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Citius Oncology does not currently pay a dividend.

Dividend Growth

Citius Oncology does not have a long track record of dividend growth.

News and Social Media

• Score: 4.2 / 5
• News Sentiment: 0.79

News Sentiment

Citius Oncology has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Citius Oncology this week, compared to 2 articles on an average week.

Search Interest

1 people have searched for CTOR on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Citius Oncology to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Citius Oncology insiders have not sold or bought any company stock.

Percentage Held by Insiders

9.82% of the stock of Citius Oncology is held by insiders.

Percentage Held by Institutions

70.52% of the stock of Citius Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 10/27/2026
• Next Earnings (Estimated): 12/17/2026
• Fiscal Year End: 9/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CTOR
• Previous Symbol: NASDAQ:CTOR
• CIK: 1851484
• Web: www.citiusonc.com
• Phone: (908) 967-6677
• Fax: N/A
• Employees: 285
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $7.11 million
• Price / Sales: 8.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 92,981,000
• Free Float: 83,850,000
• Market Cap: $56.81 million
• Optionable: N/A
• Beta: 3.39